These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga

08/14

Altimmune, Inc. (NASDAQ:ALT) posted a loss for the second quarter on Tuesday.

The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.

“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”

Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.

These analysts made changes to their price targets on Altimmune following earnings announcement.

B. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.
UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.
HC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.

Considering buying ALT stock? Here’s what analysts think:

Read This Next:

Top 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559986600"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559986600\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559986600?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 02:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559986600","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On Altimmune Following Q2 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On Altimmune Following Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On Altimmune Following Q2 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-08-14 02:57</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/47103330/these-analysts-slash-their-forecasts-on-altimmune-following-q2-results","article_id":"2559986600","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559986600","pubTimestamp":1755111443,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","ALT":"Altimmune, Inc.","BK4599":"减肥药"},"translate_title":"这些分析师在第二季度业绩公布后大幅下调了对Altimmune的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune, Inc. (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.\nThe company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.\n“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”\nAltimmune shares gained 5.7% to trade at $3.8250 on Wednesday.\nThese analysts made changes to their price targets on Altimmune following earnings announcement.\n\nB. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.\nUBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.\nHC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.\n\nConsidering buying ALT stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}